Notably, the GLYCOV exhibited superior performance (95% sensitivity and 80% specificity) compared with CA125 (60% sensitivity and 65% specificity) in distinguishing early-stage epithelial ovarian cancer patients from benign ovarian disease patients. Here, MUC16 is linked to ovarian carcinoma.